Claims for Patent: 7,067,279

Summary for Patent: 7,067,279

Title:	Cell culture performance with betaine
Abstract:	This invention relates generally to the field of cell culture. More particularly, the invention relates to improving viability of recombinant cell cultures and the yields of secreted polypeptides therefrom by the addition of betaine to the tissue culture medium.
Inventor(s):	Follstad; Brian D. (Seattle, WA), Potter; Anne H. (Sammamish, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	10/226,931
Patent Claims:	1. A method comprising culturing a recombinantly engineered animal cell line in tissue culture medium, wherein the cell line is recombinantly engineered to express a polypeptide of interest, the medium has an effective amount of betaine and the tissue culture medium is not hyperosmotic, whereby cell survival and expression of said polypeptide of interest are improved relative to cells grown without betaine, wherein the cells are grown during a proliferative phase in the absence of betaine, and in the presence of betaine in an induction phase. 2. The method of claim 1, wherein the culture medium is serum free. 3. The method of claim 2, wherein the recombinantly engineered cell line is a mammalian cell line. 4. The method of claim 3, wherein the mammalian cell line is selected from the group consisting of CHO, VERO, BHK, HeLa, Cos, MDCK, 293, 3T3, a myeloma cell line, a hybridoma cell line, and WI38 cells. 5. The method of claim 4, wherein the tissue culture medium is serum free. 6. The method of claim 1, wherein the betaine is selected from the group consisting of glycine betaine and betaine aldehyde. 7. The method of claim 6, wherein cell survival is improved by about 20%. 8. The method of claim 7, wherein the betaine is at a concentration of about 20 mM. 9. The method of claim 8, wherein the polypeptide of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble flt3 ligand, a soluble CD40 ligand, an erythropoietin, an antibody, an Fc-fusion protein, a calcitonin, a growth hormone, an insulin, an insulinotropin, insulin-like growth factors, a parathyroid hormone, an interferons, a nerve growth factor, a glucagons, an interleukins, a colony stimulating factor, a glucocerebrosidase, a superoxide dismutase, a tissue plasminogen activator, a Factor VIII, a Factor IX, an apolipoprotein E, an Apolipoprotein A-I, a globin, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, and an alpha-galactosidase A. 10. The method of claim 9, wherein the cell line is cultured in a bioreactor. 11. The method of claim 10, further comprising collecting the protein of interest. 12. The method of claim 11, wherein the cell line is grown in suspension culture. 13. A cell culture comprising a recombinantly engineered animal cell in tissue culture medium, wherein the cell line is recombinantly engineered to express a protein of interest, the medium has an amount of betaine effective to improve cell survival and expression of said protein of interest and the tissue culture medium is not hyperosmotic, wherein the cells are grown during a proliferative phase in the absence of betaine, and in the presence of betaine in an induction phase. 14. The cell culture of claim 13, wherein the recombinantly engineered cell line is mammalian cell line. 15. The cell culture of claim 14, wherein the culture medium is serum free. 16. The cell culture of claim 15, wherein the recombinantly engineered cell line is a mammalian cell line. 17. The cell culture of claim 16, wherein the mammalian cell line is selected from the group consisting of CHO, VERO, BHK, HeLa, Cos, MDCK, 293, 3T3, a myeloma cell line, a hybridoma cell line, and WI38 cells. 18. The cell culture of claim 17, wherein the tissue culture medium is serum free. 19. The cell culture of claim 13, wherein the betaine is selected from the group consisting of glycine betaine and betaine aldehyde. 20. The cell culture of claim 19, wherein cell survival is improved by about 20%. 21. The cell culture of claim 20, wherein the betaine is at a concentration of about 20 mM. 22. The cell culture of claim 21, wherein the polypeptide of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble flt3 ligand, a soluble CD40 ligand, an erythropoietin, an antibody, an Fc-fusion protein, a calcitonin, a growth hormone, an insulin, an insulinotropin, insulin-like growth factors, a parathyroid hormone, an interferons, a nerve growth factor, a glucagons, an interleukins, a colony stimulation factor, a glucocerebrosidase, a superoxide dismutase, a tissue plasminogen activator, a Factor VIII, a Factor IX, an aploipoprotein E, an Apolipoprotein A-I, a globin, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, and an alpha-galactosidase A. 23. The cell culture of claim 22, wherein the cell line is cultured in a bioreactor. 24. The cell culture of claim 23, further comprising collecting the protein of interest. 25. The cell culture of claim 23, wherein the cell line is grown in suspension culture.

Details for Patent 7,067,279

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-03-29